This page shows the latest ramucirumab news and features for those working in and with pharma, biotech and healthcare.
The Oncologic Drugs Advisory Committee of the FDA reviewed the safety and efficacy data from the phase 3 RELAY trial of Cyramza (ramucirumab) in patients with EGFR-positive NSCLC, which is
It also sells gastrointestinal cancer antibodies Erbitux (cetuximab) and recently launched Cyramza (ramucirumab), but was a late entrant into the cancer immunotherapy sector, and the Armo deal is viewed as a
The FDA approval is for Cyramza (ramucirumab) – a VEGF receptor 2 antagonist – as a second-line treatment after Bayer’s multikinase inhibitor Nexavar (sorafenib), often used as a first-line targeted
along with other newer cancer drugs such as Cyramza (ramucirumab).
treated previously with intravenous VEGF drugs, such as Roche’s Avastin (bevacizumab) and Lilly’s Cyramza (ramucirumab).
It also sells gastrointestinal cancer antibodies Erbitux (cetuximab) and recently launched Cyramza (ramucirumab).
More from news
Approximately 9 fully matching, plus 32 partially matching documents found.
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...